{"doi":"10.1517/13543776.17.7.745","title":"Histone deacetylase inhibitors","abstract":null,"journal":"Expert Opinion on Therapeutic Patents","year":2007,"id":45385,"datarank":0.9806759359153503,"base_score":2.5649493574615367,"endowment":2.5649493574615367,"self_citation_contribution":0.38474240361923057,"citation_network_contribution":0.5959335322961198,"self_endowment_contribution":0.38474240361923057,"citer_contribution":0.5959335322961198,"corpus_percentile":null,"corpus_rank":null,"citation_count":12,"citer_count":12,"citers_with_citation_signal":12,"citers_with_endowment":12,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":212056,"name":"Hazel J Dyke","orcid":null,"position":1,"is_corresponding":false},{"id":212055,"name":"Steve Price","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":2.5649493574615367,"endowment":2.5649493574615367,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21071399","pmcid":null,"openalex_id":"https://openalex.org/W2516856182","authors":[],"funders":[],"total_grants":0,"fwci":0.8076,"citation_percentile":0.72264698,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2014,"count":1},{"year":2021,"count":2},{"year":2022,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://www.tandfonline.com/doi/pdf/10.1517/13543776.17.7.745","host_type":"publisher"},{"url":"https://doi.org/10.1517/13543776.17.7.745","host_type":"journal"}],"fields_of_study":["Histone Deacetylase Inhibitors Research","Protein Degradation and Inhibitors","Ubiquitin and proteasome pathways","Biology","Medicine"],"mesh_terms":[],"keywords":["Vorinostat","Histone deacetylase","Histone deacetylase inhibitor","Pharmacology","Hydroxamic acid","Medicine","Cancer research","Histone","Chemistry","Biochemistry","Stereochemistry"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-03T01:19:32.377669Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}